electroCore Surges on Strong Revenue Beat and 26% Growth Forecast for 2025
The medical device maker's preliminary Q4 sales surpassed analyst estimates by over 14%, signaling accelerating demand for its nerve stimulation therapies.
Shares of electroCore Inc. (NASDAQ: ECOR) climbed on Tuesday after the medical technology company announced preliminary fourth-quarter revenue that significantly outpaced Wall Street expectations and issued a bullish growth forecast for the full year.
The company, which specializes in non-invasive nerve stimulation therapies, saw its stock rise more than 5% in trading as investors reacted to the strong top-line performance and optimistic outlook for 2025.
In a business update, electroCore reported preliminary unaudited revenue for the fourth quarter is expected to be between $9.0 million and $9.2 million. The midpoint of this range, $9.1 million, represents a roughly 30% increase over the same period in the prior year and comfortably beats the consensus analyst estimate of $7.9 million by more than 14%. The strong quarter capped a year where the company generated $25.2 million in total revenue.
Looking ahead, electroCore projected full-year 2025 revenue to be in the range of $31.8 million to $32.0 million. This forecast implies a substantial 26% year-over-year growth, indicating that management anticipates the commercial momentum to continue building. The full details were released in a statement on GlobeNewswire.
Based in New Jersey, electroCore is pioneering the use of non-invasive vagus nerve stimulation (nVNS) to treat a variety of medical conditions. Its flagship prescription product, gammaCore, is used for the treatment of headache and migraine pain. The company is also expanding its platform into wellness and human performance applications with products like Truvaga.
Despite the positive revenue news, the company's cash position saw a decline. As of December 31, 2025, electroCore held approximately $11.6 million in cash, cash equivalents, and marketable securities, down from $13.2 million at the end of the third quarter, according to its Form 8-K filing with the SEC.
Even with the stock's recent gains, Wall Street analysts see significant further upside. The company is covered by five analysts who have collectively set an average price target of $21.14, suggesting a potential increase of over 200% from its current levels. All five analysts rate the stock as either a 'Buy' or 'Strong Buy', signaling strong confidence in the company's growth trajectory and technology platform.
The robust guidance suggests that electroCore is reaching an inflection point in the adoption of its bioelectronic therapies. Investors will be looking for more detailed commentary on the drivers of this growth and the company's path to profitability when it hosts its full financial results call in March.